64917-99-3

Basic information

• Product Name: Pentanoic acid, 2-isocyanato-4-methyl-, phenylmethyl ester, (S)-
• CAS NO: 64917-99-3
• Molecular Formula: C14H17NO3
• Molecular Weight: 247.294
• Mol File: 64917-99-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Pentanoic acid, 2-isocyanato-4-methyl-, phenylmethyl ester, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanoic acid, 2-isocyanato-4-methyl-, phenylmethyl ester, (S)-(64917-99-3)
• EPA Substance Registry System: Pentanoic acid, 2-isocyanato-4-methyl-, phenylmethyl ester, (S)-(64917-99-3)

Safety Data

• Hazardous Substances Data: 64917-99-3(Hazardous Substances Data)

Upstream product

• 2462-35-3 L-leucine benzyl ester hydrochloride 
• 503-38-8 trichloromethyl chloroformate 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 1738-77-8 L-leucine benzyl ester p-toluenesulfonate 
• 80089-22-1 L-leucine (phenylmethyl)ester 

Downstream Products

• 141595-75-7 (S)-2-[(azepane-1-carbonyl)-amino]-4-methyl-pentanoic acid benzyl ester 

Relevant articles and documents

Synthesis and biological evaluation of novel 10-substituted-7- Ethyl-10-hydroxycamptothecin (SN-38) prodrugs

In an attempt to improve the antitumor activity and reduce the side effects of irinotecan (2), novel prodrugs of SN-38 ( 3) were prepared by conjugating amino acids or dipeptides to the 10-hydroxyl group of SN-38 via a carbamate linkage. The synthesized compounds completely generated SN-38 in pH 7.4 buffer or in human plasma, while remaining stable under acidic conditions. All prodrug compounds demonstrated much greater in vitro antitumor activities against HeLa cells and SGC-7901 cells than irinotecan. The most active compounds, 5h, 7c, 7d, and 7f, exhibited IC50 values that were 1000 times lower against HeLa cells and 30 times lower against SGC-7901 cells than those of irinotecan, and the inhibitory activities of these prodrugs against acetylcholinesterase (AchE) were significantly reduced, with IC50 values more than 6.8 times greater than that of irinotecan. In addition, compound 5e exhibited the same level of tumor growth inhibitory activity as irinotecan (CPT-11) in a human colon xenograft model in vivo.

Peptide compound and its preparation

Novel peptides of the formula (I") STR1 in which R1 is hydrogen or acyl, R2c is lower alkyl, R3c is optionally N-substituted indolylmethyl, R4 is hydrogen, lower alkyl, C6-10 ar(lower)alkyl, amino(lower)alkyl, protected amino (lower)alkyl, carboxy(lower)alkyl, protected carboxy(lower)alkyl or optionally substituted heterocyclic (lower)alkyl, R5 is carboxy, protected carboxy, carboxy(lower)alkyl or protected carboxy(lower)alkyl, R7 is hydrogen or lower alkyl, and A is --O--, --NH--, lower alkylamino or lower alkylene, or a pharmaceutically acceptable salt thereof are disclosed. Additionally, the preparation of such peptides is described. The peptides are used to treat endothelin mediated diseases such as hypertension.